|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **HV group** | **PD group** | Stats | p | **PD group 1** | **PD group 2** | **PD group 3** | Stats | p |
| Volunteers | 20 | 70 |  |  | 23 | 22 | 25 |  |  |
| Age (years) | 53.11 ± 11.7 | 55.78 ± 7.22 | t=3.38(23.18) | 0.347 | 55.78 ± 7.76 | 54.66 ± 5.08 | 57.26 ± 8.51 | F=0.694(2,67) | 0.558 |
| Gender (m:f)  | 10:10 | 52:18 | χ²=4.28(1) | 0.039 | 15:8 | 15:7 | 22:3 | χ²=7.74(2) | 0.052 |
| Disease duration | NA | 5.39 ± 2.45 |  | -- | 4.33 ± 1.97 | 6.19 ± 2.29 | 5.62 ± 2.71 | F=3.77(2,67) | 0.028 |
| UPDRS-III  | NA | 31.47 ± 11.56 |  | -- | 19.3 ± 3.11 | 29.27 + 3.13 | 44.60 ± 6.42 | F=213.9(2,67) | ***0.0001*** |
| Hoehn and Yahr scale  | NA | 1.87 ± 0.47 |  | -- | 1.63 ± 0.48 | 1.86 ± 0.46 | 2.12 ± 0.33 | F=7.07(2,67) | 0.01 |
| LEDD  | NA | 563 ± 344 |  | -- | 411 ± 244 | 647 ± 431 | 640 ± 313 | F=3.11(2,67) | 0.03 |

**Table 1**: Demographic and clinical characteristics of HV and PD groups. PD patients were subdivided into 3 disease severity groups using UPDRS-III tertile calculations. Values represent the mean±SD. NA=not applicable; UPDRS-III=Unified Parkinson’s Disease Rating Scale Part-III; LEDD=Levodopa equivalent daily dose.